Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 253-039-2 | CAS number: 36443-68-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicity to reproduction
Administrative data
- Endpoint:
- two-generation reproductive toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From Jan. 22, 1988 to Oct. 16, 1990
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 990
- Report date:
- 1990
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 416 (Two-Generation Reproduction Toxicity Study)
- Deviations:
- yes
- Remarks:
- Estrous cycle not measured prior to mating, sperm parameters not examined. Content in feed not adjusted for food consumption
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 83-4 (Reproduction and Fertility Effects)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Ethylenebis(oxyethylene) bis[3-(5-tert-butyl-4-hydroxy-m-tolyl)propionate]
- EC Number:
- 253-039-2
- EC Name:
- Ethylenebis(oxyethylene) bis[3-(5-tert-butyl-4-hydroxy-m-tolyl)propionate]
- Cas Number:
- 36443-68-2
- Molecular formula:
- C34H50O8
- IUPAC Name:
- ethane-1,2-diylbis(oxyethane-2,1-diyl) bis[3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propanoate]
- Details on test material:
- - Physical State: solid
- Storage condition of test material: room temperature
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Wiga GmBH
- Age at study initiation: aproximately 6 weeks
- Weight at study initiation: (P) Males: 165-220g; Females: 140-175g;
- Fasting period before study: None
- Housing:individually in solid floor macrolone cages
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 17 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-25
- Humidity (%): 40-70
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: February 1, 1988 To: February 1, 1989
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): every 2 weeks
- Mixing appropriate amounts with (Type of food): powdered food
- Storage temperature of food: room temp
VEHICLE
- Justification for use and choice of vehicle (if other than water): Not applicable, test substance mixed in diet - Details on mating procedure:
- - M/F ratio per cage: 1/1
- Length of cohabitation: up to 3 weeks
- Proof of pregnancy: vaginal plug / sperm in vaginal smear referred to as day 0 of pregnancy
- After successful mating each pregnant female was caged: individually
- Each male was mated with one female from the same dose groups for up to 3 weeks
- Further matings after two unsuccessful attempts: No
- After successful mating each pregnant female was caged: individually except during lactation, when each female was housed with its litter.
- Any other deviations from standard protocol: No - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- 10 gram samples of the test article were taken once after receipt of the test article (before initiation of the study), once after the start of the in-life phase, once before start of treatment of the Fl generation, and once at the end of the in-life phase and sent to the study sponsor on 26.05.1987, 21.01.1988, 30.06.1988, or 03.02.1989, respectively, for analysis.
In order to verify accurate preparation of the admixtures of the test article to the powdered diet, formulations prepared for this study were analysed for determination of test article concentration, homogeneity, and stability (over two and four week intervals). Analytical examinations of
the formulation preparations from 29.01.1988 until 20.06.1988 (prior to the completion of the new analytical laboratory at Hazleton Laboratories Deutschland GmbH) were performed by Mr. Frank Harhoff, Institut fiir Laboratoriumsmedizin, BrauhausstraBe 4, 4600 Dortmund 1, West Germany. An HPLC method was used. - Duration of treatment / exposure:
- For both P and F1 generations (during first pre-mating treatment of 100 days, during mating aprox 21 days, gestation approx 21 days and lactation approx 21 days;second pre-mating treatment of 14 days, during second mating aprox 21 days, gestation approx 21 days and lactation approx 21 days ).
- Frequency of treatment:
- Daily - In diet ad libitum
- Details on study schedule:
- After 100 days of premating treatment, the P parental animals were mated for up to 21 days and the females were allowed to litter and to rear their offspring (F1a generation) to weaning. Approximately 14 days after all the F1a offspring were weaned, the P parental animals were paired again, within the dose groups, for up to 21 days. Alternative pairings from the first mating were employed. The P females were allowed to litter and to rear their offspring (F1b generation) to weaning.
After a 100 days maturation period after weaning, the F1 parental animals (selected from the F1a offspring) were mated for up to 21 days and the females were allowed to litter and to rear their offspring (F2a generation) to weaning. Approximately 14 days after all the F2a offspring were weaned, the F1 parental animals were paired again, within the dose groups, for up to 21 days. Alternative pairings from the first mating were employed. The F1 females were allowed to litter and to rear their offspring (F2b generation) to weaning.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 300 ppm
- Remarks:
- corresponding to 21 - 26 mg/kg bw/day; peak exposure of up to 53 mg/kg bw/day during lactation
- Dose / conc.:
- 900 ppm
- Remarks:
- corresponding to 60 - 80 mg/kg bw; peak exposure of up to 124 mg/kg bw/day during lactation
- Dose / conc.:
- 1 800 ppm
- Remarks:
- corresponding to 120 - 160 mg/kg bw/d; peak exposure of up to 246 mg/kg bw/day during lactation
- No. of animals per sex per dose:
- P generation = 30/sex/group
F1 generation = 25/sex/group (pairing 1), 26males and 24 fermales/group (pairing 2) - Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale: the dose levels were selected on the basis of the results from previous acute oral, 90 day oral, oral teratogenicity, and dose range-finding studies.
- Rationale for animal assignment (if not random): random
Administration at 300 ppm corresponds approximately to a 21 to 26 mg/kg/day dose level if calculated as the overall mean of the weekly mean values of mean daily test article intake (the overall mean of P and F1 males corresponds to approximately
21 mg/kg/day dose level - range of the weekly mean values 14.6 to 47.3 mg/kg/day - and the overall mean of P and F1 females corresponds to
approximately 26 mg/kg/day dose level if the gestation and lactation periods are excluded - range of the weekly mean values 20.5 to 47.6 mg/kg/day). - Positive control:
- None
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: once daily
- Cage side observations checked in table were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once daily
BODY WEIGHT: Yes
- Time schedule for examinations: once weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
- Time schedule for examinations: NA - Oestrous cyclicity (parental animals):
- Not reported.
Cervix, ovaries, uterus, and vagina tissues were examined by the study histopathologist - Sperm parameters (parental animals):
- Parameters examined in all male parental generations: epididymides, prostate, seminal vesicles, and testes tissue were examined by the study histopathologist
- Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: yes
- If yes, maximum of 8 pups/litter (4/sex/litter as nearly as possible); excess pups were killed and discarded.
PARAMETERS EXAMINED
The following parameters were examined in F1 / F2 offspring:
number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, weight gain, physical or behavioural abnormalities, physical developement
GROSS EXAMINATION OF DEAD PUPS:
yes, for external and internal abnormalities; possible cause of death was determined for pups born or found dead. - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals shortly after their second mating period.
- Maternal animals: All surviving animals after weaning of the second litter.
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations in F1 generation.
HISTOPATHOLOGY / ORGAN WEIGHTS
Tissues were prepared for microscopic examination and weighed. - Postmortem examinations (offspring):
- SACRIFICE
- The F1 offspring not selected as parental animals and all F2 offspring were sacrificed shortly after weaning or after selection is completed (age at selection not clear).
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations
HISTOPATHOLOGY / ORGAN WEIGTHS
Tissues were prepared for microscopic examination and weighed. - Statistics:
- Analysis of Variance followed by the Student-Newman-Keuls test for multiple group comparisons.
- Reproductive indices:
- Mating performance (d)
Insemination index (%)
Fecundity index
Fertility index
Gestation index - Offspring viability indices:
- Live birth index (%)
Weaning index (%)
Viability index (d4-1)
Viability index (d7-4)
Viability index (d7-14)
Viability index (d14-21)
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Swelling of mouth and forelimb, loss of fur, blood in bedding, inflammation of eyes, cystoliths in urinary bladder, and atrophy of testes were observed in a few animals of varying dose groups; however, due to their nature and low incidence, these clinical observations and necropsy findings were considered incidental.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Males: mean body weight gain of high dose group was slightly lower than control group
Females: mean body weight gain of high dose group was slightly lower than control group and statistically significant weeks 2 and 7 of treatment and day 14 to 21 of lactation - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- At 1800 ppm (group 4), mean daily food consumption of the male animals of the P generation was slightly reduced prior first and second mating. This is considered attributable to treatment. In the females of the P generation, mean daily food consumption of the animals of group 4 (1800 ppm) was reduced prior first mating and continuously until second lactation.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- A few microscopic changes were observed however they were considered to be incidental findings or background pathology
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Test substance intake: During first lactation, mean daily food consumption was dosage-relatedly reduced in groups 3 (900 ppm) and 4 (1800 ppm) and comparable with the control in group 2 (300 ppm). Differences between groups 3 (300 ppm) and 4 (1800 ppm) and the control group wer
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- Indices did not reveal any differences between dose groups and control.
Effect levels (P0)
- Dose descriptor:
- NOEL
- Effect level:
- 300 ppm (analytical)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
Results: P1 (second parental generation)
General toxicity (P1)
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- In the male animals, mean body weight gain prior and during first and second mating was - if compared for each of the individual intervals recorded - generally comparable in all groups. For only few of these individual intervals prior and during first mating, the observed differences between groups 3 (900 ppm) or 4 (1800 ppm) and the control were statistically significant; in most of these cases, body weight gain was significantly lower than the control. If the overall treatment period prior start of first mating is taken as the basis for comparison, mean body weight gain of all dose groups was lower than in the control group. The difference to the control group was biggest in group 4 (1800 ppm). This finding was therefore considered to be treatment-related in the high dose group. Body weight development in females was not different to controls.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Mean daily food consumption of the male animals of group 4 (1800 ppm) was lower than in the control group. The female animals in group 4 (1800 ppm) of this generation showed reduced mean daily food consumption during first lactation, prior second mating, and during second lactation, or in group 3 (900 ppm), mainly prior second mating.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In the male animals of the Fl generation, the lower mean spleen weight and the moderately increased mean kidney weight in group 4 (1800 ppm) as well as the slightly increased mean kidney weight in group 3 (900 ppm) cannot definitively be related to treatment but a treatment-relationship is considered possible in both groups. The observed slight inter-group variations in the mean organ weights of the Fl female animals are considered not to be attributable to treatment.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Although colour changes of the kidneys are regularly observed in this strain of rats, the increased incidence of yellowish kidneys in group 4 (1800 ppm) is considered treatment-related (males and females).
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A few microscopic changes were observed however they were considered to be incidental findings or background pathology
- Histopathological findings: neoplastic:
- not examined
Reproductive function / performance (P1)
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- Indices did not reveal any differences between dose groups and control.
Effect levels (P1)
- Dose descriptor:
- NOEL
- Effect level:
- 300 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- organ weights and organ / body weight ratios
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Slight retardation of hair growth and eye opening in high dose group; physical development of low and mid dose group was similar to control
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, treatment-related
- Description (incidence and severity):
- Pup losses of mid and high dose groups were slightly higher than control (reported to be minimal however significance not indicated)
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Mean body weights reduced in mid and high dose groups (significant on days 1, 4, 14 and 21 post-partum for high dose group and significant on days 4 and 21 for the mid dose group)
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Low incidence of malformations and abnormalities were observed however, these types of malformations are known to occur spontaneously in rats and due to their low incidence, they were considered incidental
- Histopathological findings:
- not examined
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- In the F1a generation, results of the employed functional tests underlined or are considered likely to underline the observed retardation of pup development at 1800 ppm (group 4), respectively, but did not reveal any additional treatment-related effect. In the F1b group, functional tests did not show any differences between dose groups and control group.
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not examined
Effect levels (F1)
open allclose all
- Dose descriptor:
- NOEL
- Generation:
- F1a
- Effect level:
- 300 ppm (analytical)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- mortality
- body weight and weight gain
- Dose descriptor:
- NOEL
- Generation:
- F1b
- Effect level:
- 300 ppm (analytical)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- mortality
- body weight and weight gain
Results: F2 generation
General toxicity (F2)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Slight retardation of hair growth and eye opening in high dose group; physical development of low and mid dose group was similar to control
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, treatment-related
- Description (incidence and severity):
- In the F2a generation, the lower mean numbers of pups found alive on day 1 post-partum in groups 3 (900 ppm) and 4 (1800 ppm) cannot definitively be related to treatment as the differences to the control group were small.
In the F2b generation, the moderately reduced mean number of pups found alive on day 1 post-partum in group 4 (1800 ppm) is considered treatment-related.
During lactation, F2a pup losses from day 1 to 4 post-partum were slightly increased in groups 3 (900 ppm) and 4 (1800 ppm). In the F2b generation, pup losses were slightly increased in group 3 (900 ppm) and markedly increased in group 4 (1800 ppm). These findings are considered attributable to treatment. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Mean pup weight was slightly reduced in low dose group, slightly to moderately reduced in mid dose group, and markedly reduced in high dose group (significant on days 14 and 21 for all groups however, only mid and high dose groups effects were definitively related to treatment)
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Low incidence of malformations and abnormalities were observed however, these types of malformations are known to occur spontaneously in rats and due to their low incidence, they were considered incidental
- Histopathological findings:
- not examined
Developmental neurotoxicity (F2)
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- In the F2b generation, results of the employed functional tests underlined or are considered likely to underline the observed retardation of pup development at 1800 ppm (group 4), respectively, but did not reveal any additional treatment-related effect. In the F2a pups, functional tests did not show any differences between dose groups and control group.
Developmental immunotoxicity (F2)
- Developmental immunotoxicity:
- not examined
Effect levels (F2)
open allclose all
- Dose descriptor:
- NOEL
- Generation:
- F2a
- Effect level:
- 300 ppm (analytical)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- mortality
- body weight and weight gain
- Dose descriptor:
- NOEL
- Generation:
- F2b
- Effect level:
- 300 ppm (analytical)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- mortality
- body weight and weight gain
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Any other information on results incl. tables
Table 1: Overview on indices
P-generation | F1-generation | |||||||||||||||||||
1rst mating | 2nd mating | 1rst mating | 2nd mating | |||||||||||||||||
Dose (ppm) | 0 | 300 | 900 | 1800 | 0 | 300 | 900 | 1800 | 0 | 300 | 900 | 1800 | 0 | 300 | 900 | 1800 | ||||
Mating performance (d) | 2.4 | 2.5 | 2.9 | 2.5 | 96.7 | 96.7 | 93.3 | 100 | 2.4 | 2.7 | 2.6 | 2.6 | 2.3 | 2.1 | 2.8 | 1.8 | ||||
Insemination index (%) | 96.7 | 93.3 | 100 | 96.7 | 96.7 | 96.7 | 93.3 | 100 | 100 | 95.8 | 96 | 100 | 92 | 95.8 | 100 | 100 | ||||
Fecundity index | 96.6 | 100 | 96.7 | 100 | 89.7 | 79.3 | 85.7 | 90 | 88 | 100 | 87.5 | 96 | 73.9 | 91.3 | 80 | 88 | ||||
Fertility index | 93.3 | 93.3 | 96.7 | 96.7 | 86.7 | 76.7 | 80 | 90 | 88 | 95.8 | 84 | 96 | 68 | 87.5 | 80 | 88 | ||||
Gestation index | 100 | 100 | 100 | 100 | 100 | 100 | 95.8 | 96.3 | 100 | 100 | 100 | 100 | 100 | 100 | 95 | 100 | ||||
F1a-generation | F1b -generation | F2a -generation | F2b -generation | |||||||||||||||||
Dose (ppm) | 0 | 300 | 900 | 1800 | 0 | 300 | 900 | 1800 | 0 | 300 | 900 | 1800 | 0 | 300 | 900 | 1800 | ||||
Live birth index (%) | 98.4 | 98.3 | 92.5 | 90.9 | 96 | 98.6 | 95.6 | 95.4 | 98.3 | 93.8 | 90.2 | 92.6 | 97.6 | 98.2 | 97.3 | 92.6 | ||||
Weaning index (%) | 59.4 | 59.8 | 49.1 | 47.8 | 89.2 | 75.7 | 59.7 | 47.6 | 80.4 | 84.8 | 75.5 | 74.8 | 64.7 | 68.1 | 59.6 | 36.8 | ||||
Viability index (d4-1) | 96.9 | 94 | 89.5 | 81.2 | 94.7 | 96.6 | 86.2 | 80.2 | 93.1 | 96.9 | 80 | 78.2 | 92.9 | 93.9 | 76.3 | 65.9 | ||||
Viability index (d7-4) | 96.4 | 84.8 | 80.8 | 80.5 | 87.5 | 96.2 | 80.1 | 74.5 | 89.3 | 91.8 | 82.5 | 83.9 | 83.8 | 87.5 | 76.2 | 58.4 | ||||
Viability index (d7-14) | 62.3 | 66.1 | 64.4 | 58.3 | 76.8 | 78.8 | 75.6 | 61.5 | 85.3 | 93.8 | 87.8 | 89.7 | 72.2 | 78.7 | 76.4 | 56.3 | ||||
Viability index (d14-21) | 91.8 | 93.5 | 91.6 | 94.8 | 94.9 | 96.6 | 98 | 93.7 | 96.8 | 98 | 98.5 | 97.9 | 98.8 | 95.7 | 94.7 | 85.2 |
Table 2: Group mean body weight (g) of females during first lactation (calculated from animals with live pups on day 21 pp) |
|||||||||||||||||
Parameter | 0 ppm (group 1) | 300 ppm (group 2) | 900 ppm (group 3) | 1800 ppm (group 4) | ANOVA | ||||||||||||
Day of lactation | N | mean | SD | N | mean | SD | N | mean | SD | N | mean | SD | F-probability | ||||
1 | 24 | 305.2 | 23.1 | 23 | 299.1 | 20.5 | 24 | 306.6 | 19.9 | 22 | 285 | 22.2 | (1,2,3) | 0.0141 | |||
4 | 24 | 312.3 | 28.1 | 23 | 306.1 | 22.1 | 24 | 310 | 18.2 | 22 | 291.8 | 24.7 | (1,2,3) | 0.02 | |||
7 | 24 | 315.8 | 29 | 23 | 312 | 22.7 | 24 | 311.7 | 21.8 | 22 | 298.4 | 24.3 | 0.0994 | ||||
14 | 24 | 331.7 | 27.8 | 23 | 325.9 | 20 | 24 | 325 | 18.7 | 21 | 312.9 | 24.1 | 0.0561 | ||||
21 | 24 | 325 | 25.4 | 23 | 322.6 | 20.7 | 24 | 322.7 | 21.1 | 22 | 320.9 | 22.9 | 0.9433 | ||||
(gr n) = group number which is significantly different from the marked group; p < 0.05, analysis of variance followed by Newman-Keuls test | |||||||||||||||||
Table 3: Group mean daily food consumption (g/d) of females during first lactation (calculated from animals with live pups on day 21 pp) | |||||||||||||||||
Parameter | 0 ppm (group 1) | 300 ppm (group 2) | 900 ppm (group 3) | 1800 ppm (group 4) | ANOVA | ||||||||||||
Day of lactation | N | mean | SD | N | mean | SD | N | mean | SD | N | mean | SD | F-probability | ||||
1 | 24 | 30.5 | 5.6 | 23 | 31.7 | 4.7 | 24 | 29.8 | 5.3 | 22 | 29.4 | 5.9 | 0.5132 | ||||
4 | 24 | 35.4 | 8.2 | 23 | 36.6 | 5 | 24 | 33.6 | 4.8 | 22 | 32.8 | 4.9 | 0.1337 | ||||
7 | 24 | 45.1 | 10.4 | 23 | 45.7 | 6.5 | 24 | 39 | 7.6 | (1,2) | 22 | 37.7 | 5.8 | (1,2) | 0.0006 | ||
14 | 24 | 56.8 | 17.6 | 23 | 57.4 | 14.8 | 24 | 44.7 | 12.9 | (1,2) | 22 | 43.5 | 9.2 | (1,2) | 0.0004 | ||
21 | 24 | 45.6 | 11 | 23 | 46.3 | 7.6 | 24 | 38.8 | 7.6 | (1,2) | 22 | 37.8 | 5.8 | (1,2) | 0.0004 | ||
(gr n) = group number which is significantly different from the marked group; p < 0.05, analysis of variance followed by Newman-Keuls test |
Table 4 : Litter weights and pup weights of the F1a generation | |||||||||||||||||
Parameter | 0 ppm (group 1) | 300 ppm (group 2) | 900 ppm (group 3) | 1800 ppm (group 4) | ANOVA | ||||||||||||
N | mean | SD | N | mean | SD | N | mean | SD | N | mean | SD | F-probability | |||||
Number of pups day 1 pp | 28 | 12.5 | 2.4 | 28 | 12.5 | 2.2 | 29 | 12 | 3.2 | 29 | 11.7 | 2.6 | 0.6014* | ||||
Litter weight day 1 pp | 28 | 80 | 14.9 | 28 | 77.8 | 12.4 | 29 | 73.5 | 19.9 | 29 | 70.5 | 16.6 | 0.1219 | ||||
Pup weight day 1 pp | 28 | 6.4 | 0.5 | 28 | 6.3 | 0.6 | 29 | 6.1 | 0.6 | 29 | 6 | 0.6 | (gr.1) | 0.0761* | |||
Number of pups day 4 pp | 28 | 12.1 | 2.2 | 28 | 11.6 | 2.7 | 29 | 11.1 | 3.6 | 29 | 9.8 | 3.2 | (Gr 1,2,3) | 0.0164* | |||
Litter weight day 4 pp | 28 | 98.5 | 21.5 | 28 | 93 | 27.1 | 28 | 84.9 | 26.1 | 28 | 73.7 | 25.2 | (gr 1,2) | 0.0023 | |||
Pup weight day 4 pp | 28 | 8.2 | 1.2 | 28 | 7.9 | 1.4 | 28 | 7.3 | 1.3 | (gr1) | 28 | 7.2 | 1.3 | (gr1) | 0.0108* | ||
Number of pups day 7 pp | 28 | 7.6 | 1 | 28 | 6.8 | 2.3 | 29 | 6.1 | 2.8 | (gr1) | 29 | 5.9 | 2.6 | (gr1) | 0.0119* | ||
Litter weight day 7 pp | 28 | 89.3 | 27.8 | 27 | 84.9 | 33.6 | 25 | 77.3 | 28.6 | 26 | 67.8 | 30.6 | 0.0568 | ||||
Pup weight day 7 pp | 28 | 11.7 | 2.9 | 27 | 11.5 | 3 | 25 | 10.7 | 2.6 | 26 | 9.8 | 2.6 | 0.0563* | ||||
Number of pups day 14 pp | 28 | 4.9 | 3 | 28 | 5 | 3.1 | 29 | 4 | 2.9 | 29 | 3.7 | 2.8 | 0.194* | ||||
Litter weight day 14 pp | 25 | 148.7 | 81.3 | 23 | 158.2 | 66.3 | 24 | 114.7 | 72.3 | 21 | 102.1 | 56.4 | (gr 2) | 0.0243 | |||
Pup weight day 14 pp | 25 | 25.5 | 5.5 | 23 | 25.1 | 5.1 | 24 | 22.8 | 5.2 | 21 | 20.3 | 4.9 | (gr 1,2) | 0.0008* | |||
Number of pups day 21 pp | 28 | 4.7 | 3.1 | 28 | 4.8 | 3.1 | 29 | 3.6 | 2.8 | 29 | 3.5 | 2.8 | 0.1865* | ||||
Litter weight day21 pp | 24 | 246.8 | 130.1 | 23 | 254.4 | 113.5 | 24 | 171.3 | 115 | (gr1,2) | 22 | 147.6 | 82.1 | (gr 1,2) | 0.0022 | ||
Pup weight day 21 pp | 24 | 42.3 | 8.4 | 23 | 41.6 | 7.9 | 24 | 36.4 | 8.3 | (gr1,2) | 22 | 30.6 | 7.9 | (Gr 1,2,3) | 0.0001* | ||
pp = post partum | |||||||||||||||||
(gr n) = group number which is significantly different from the marked group; p < 0.05, analysis of variance followed by Newman-Keuls test | |||||||||||||||||
* Based on taking the ranks of the variables |
Table 5 : Viability data for F1a generation | |||||||||||||||||
Parameter | 0 ppm (group 1) | 300 ppm (group 2) | 900 ppm (group 3) | 1800 ppm (group 4) | ANOVA | ||||||||||||
N | mean | SD | N | mean | SD | N | mean | SD | N | mean | SD | F-probability | |||||
Number of pups day 1 pp | 350 | 349 | 349 | 341 | |||||||||||||
Mean number per female | 28 | 12.5 | 2.4 | 28 | 12.5 | 2.2 | 29 | 12 | 3.2 | 29 | 11.7 | 2.6 | 0.7019 | ||||
Number of pups day 4 pp | 338 | 326 | 320 | 284 | |||||||||||||
mean number per female day 4 pp | 28 | 12.1 | 2.2 | 28 | 11.6 | 2.7 | 29 | 11.1 | 3.6 | 29 | 9.8 | 3.2 | (Gr 1,2) | 0.0162 | |||
Viability index % (day 4-1) | 28 | 96.9 | 4.8 | 28 | 94 | 15.8 | 28 | 89.5 | 20.2 | 28 | 81.2 | 23.5 | (gr 1,2) | 0.0049 | |||
Number of pups after adjustment of litter size | 220 | 219 | 216 | 213 | |||||||||||||
Mean number per female | 28 | 7 | 0.8 | 28 | 7.8 | 0.9 | 29 | 7.4 | 1.8 | 29 | 7.3 | 1.7 | |||||
Number of pups day 7 pp | 212 | 190 | 176 | 172 | |||||||||||||
mean number per female day 7 pp | 28 | 7.6 | 1 | 28 | 6.8 | 2.3 | 29 | 6.1 | 2.8 | (gr1) | 29 | 5.9 | 2.6 | (gr1) | 0.0119 | ||
Viability index % (day 7-4) | 28 | 96.4 | 8.9 | 28 | 84.6 | 28.9 | 28 | 80.8 | 31.8 | 29 | 80.5 | 28.8 | (gr1) | 0.0373 | |||
Number of pups day 14 pp | 137 | 139 | 115 | 107 | |||||||||||||
mean number per female day 14 pp | 28 | 4.9 | 3 | 28 | 5 | 3.1 | 29 | 4 | 2.9 | 29 | 3.7 | 2.8 | 0.194 | ||||
Viability index % (day 14-7) | 28 | 62.3 | 36.4 | 27 | 66.1 | 37 | 25 | 64.4 | 33.3 | 26 | 58.3 | 34.7 | 0.7383 | ||||
Number of pups day 21 pp | 132 | 134 | 105 | 102 | |||||||||||||
mean number per female day 21 pp | 28 | 4.7 | 3.1 | 28 | 4.8 | 3.1 | 29 | 3.6 | 2.8 | 29 | 3.5 | 2.8 | 0.1865 | ||||
Viability index % (day 21-14) | 25 | 91.6 | 23 | 23 | 93.5 | 17.2 | 24 | 91.6 | 15.6 | 22 | 94.8 | 10.3 | 0.8883 | ||||
pp = post partum | |||||||||||||||||
(gr n) = group number which is significantly different from the marked group; p < 0.05, analysis of variance followed by Newman-Keuls test | |||||||||||||||||
* Based on taking the ranks of the variables |
Table 6: Sex ratio data for F1a generation | |||||||||||||||
Parameter | 0 ppm (group 1) | 300 ppm (group 2) | 900 ppm (group 3) | 1800 ppm (group 4) | |||||||||||
males:females pp day 1 | 50.3 : 49.7 | 50.4 : 49.6 | 50.4 : 49.6 | 49.9 : 50.1 | |||||||||||
males:females pp day 21 | 49.2 : 50.8 | 49.3 : 50.7 | 53.3 : 46.7 | 52:48:00 |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
